Sopharma Overview
- Year Founded
-
1933
- Status
-
Public
- Employees
-
6,049
- Stock Symbol
-
SFA
- Investments
-
35
- Share Price
-
$3.31
- (As of Tuesday Closing)
Sopharma General Information
Description
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
Contact Information
Website
www.sopharmagroup.comCorporate Office
- 16 Iliensko Shosse Street
- Sofia, 1220
- Bulgaria
Corporate Office
- 16 Iliensko Shosse Street
- Sofia, 1220
- Bulgaria
Sopharma Timeline
Sopharma Stock Performance
As of 17-Nov-2026, Sopharma’s stock price is $3.31. Its current market cap is $1.78B with 538M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.31 | $3.37 | $1.65 - $3.97 | $1.78B | 538M | 58.9K | $0.09 |
Sopharma Financials Summary
As of 30-Jun-2026, Sopharma has a trailing 12-month revenue of $1.63B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,499,655 | 1,413,933 | 1,453,683 | |
| Revenue | 1,628,700 | 1,498,962 | 1,173,321 | 1,033,191 |
| EBITDA | 172,789 | 146,437 | 89,829 | 95,834 |
| Net Income | 94,037 | 74,183 | 42,054 | 52,878 |
| Total Assets | 1,234,493 | 1,243,075 | 951,996 | 851,552 |
| Total Debt | 327,131 | 367,125 | 254,842 | 197,316 |
Sopharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sopharma Patents
Sopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240426794-A1 | Methods of control and analysis of n-nitrosocytisine in cytisine samples | Pending | 15-Jun-2023 | ||
| WO-2024259073-A2 | Methods of control and analysis of n-nitrosocytisine in cytisine samples | Inactive | 15-Jun-2023 | ||
| WO-2024259073-A3 | Methods of control and analysis of n-nitrosocytisine in cytisine samples | Inactive | 15-Jun-2023 | ||
| AU-2019440193-A1 | Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies | Inactive | 12-Apr-2019 | ||
| CA-3126725-A1 | Oral pharmaceutical composition with a plant alkaloid for treatment of dependencies | Active | 12-Apr-2019 | A61K31/439 |
Sopharma Signals
Sopharma Investments & Acquisitions (35)
Sopharma’s most recent deal was a Merger/Acquisition with CESMA (Distributors (Healthcare)). The deal was made on 01-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CESMA (Distributors (Healthcare)) | 01-Oct-2026 | Merger/Acquisition | Distributors (Healthcare) | ||
| Pharmanova | 31-Jul-2025 | Secondary Transaction - Private | Pharmaceuticals | ||
| Sopharma (Portfolio of Pharmaceutical Product Based in Sofia, Bulgaria) | 04-Oct-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Pharmanova | 28-Aug-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Sopharma Group (Portfolio of two Pharmaceutical Products in Poland) | 01-Dec-2023 | Corporate Asset Purchase | Buildings and Property |
Sopharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Sopharma Exits (7)
Sopharma’s most recent exit was on 28-Dec-2020 from Briz. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Briz | 28-Dec-2020 | Completed |
|
||
| Aromania | 21-Jul-2017 | Completed |
|
||
| Briz | 03-Dec-2013 | Completed |
|
||
| Maritzatex | 31-Jul-2013 | Completed |
|
||
| Briz | 10-Nov-2009 | Merger/Acquisition | Completed |
Sopharma Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sopharma Trading | Sofia, Bulgaria | 2006 | |
| Pharmanova | Belgrade, Serbia | 1991 | |
| Biopharm Engineering | Sliven, Bulgaria | 1981 | |
| Vitaminy | Uman, Ukraine | 1953 |
Sopharma FAQs
-
When was Sopharma founded?
Sopharma was founded in 1933.
-
Where is Sopharma headquartered?
Sopharma is headquartered in Sofia, Bulgaria.
-
What is the size of Sopharma?
Sopharma has 6,049 total employees.
-
What industry is Sopharma in?
Sopharma’s primary industry is Distributors/Wholesale.
-
Is Sopharma a private or public company?
Sopharma is a Public company.
-
What is Sopharma’s stock symbol?
The ticker symbol for Sopharma is SFA.
-
What is the current stock price of Sopharma?
As of 17-Nov-2026 the stock price of Sopharma is $3.31.
-
What is the current market cap of Sopharma?
The current market capitalization of Sopharma is $1.78B.
-
What is Sopharma’s current revenue?
The trailing twelve month revenue for Sopharma is $1.63B.
-
What is Sopharma’s annual earnings per share (EPS)?
Sopharma’s EPS for 12 months was $0.09.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process